Benefits and Harms of ADHD Interventions: Umbrella Review and Platform for Shared Decision Making
Nov 1, 2025·,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,·
0 min read
Corentin J Gosling
Miguel Garcia-Argibay
Michele De Prisco
Gonzalo Arrondo
Anaël Ayrolles
Stéphanie Antoun
Serge Caparos
Ana Catalán
Pierre Ellul
Maja Dobrosavljevic
Luis C Farhat
Giovanna Fico
Luis Eudave
Annabeth P Groenman
Mikkel Højlund
Lucie Jurek
Mikail Nourredine
Vincenzo Oliva
Valeria Parlatini
Constantina Psyllou
Gonzalo Salazar-De-Pablo
Anneka Tomlinson
Samuel J Westwood
Andrea Cipriani
Christoph U Correll
Dong Keon Yon
Henrik Larsson
Edoardo G Ostinelli
Jae Il Shin
Paolo Fusar-Poli
John P a Ioannidis
Joaquim Radua
Marco Solmi
Richard Delorme
Samuele Cortese
Abstract
Objectives: To assess the effects of and related evidence certainty of interventions for attention deficit/hyperactivity disorder (ADHD) across an individual’s lifespan, and to develop a continuously updated web platform for people with lived experience of ADHD as a method to disseminate living evidence synthesis for shared decision making. This umbrella review of 115 eligible articles comprising 221 unique combinations of participants, interventions, comparators, and outcomes found that alpha-2 agonists, amphetamines, atomoxetine, methylphenidate, and viloxazine showed medium to large effect sizes in reducing ADHD symptom severity in children and adolescents in the short term, with moderate to high certainty evidence.
Type
Publication
BMJ